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DCM. Despite its strong correlation with left ventricular ejec-
tion fraction in CD patients, HGF failed to predict mortality 
and necessity for heart transplant in both CD and DCM pa-
tients.  Conclusions: Although HGF can be significantly in-
creased in advanced HF patients with CD and DCM, its prog-
nostic value for endpoints is minor. Therefore, the formerly 
described predictive power for HGF in HF might be restrict-
ed to specific etiologies of HF.
 Copyright © 2012 S. Karger AG, Basel
 Introduction
 Regarded by the World Health Organization as one of 
the 13 most neglected tropical diseases in the world, Cha-
gas’ disease (CD) continues to be a serious economic, so-
cial and health problem in many Latin American coun-
tries  [1] . CD is endemic throughout Central and South 
America where 16–18 million individuals are estimated 
to be infected and another 100 million are at risk of infec-
tion  [2] . Furthermore, the recent influx of immigrants 
from countries endemic for the disease has meant that 
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 Abstract
 Objectives: Hepatocyte growth factor (HGF) plays an impor-
tant role in the improvement in cardiac function and remod-
eling in a variety of cardiovascular diseases. It is also a strong 
predictor of mortality in some heart failure (HF) patients. 
However, its prognostic value in patients with Chagas’ dis-
ease (CD) or idiopathic dilated cardiomyopathy (DCM) re-
mains to be investigated.  Methods and Results: In this pro-
spective cohort study, HGF concentrations were measured 
in patients with CD (n = 91), DCM (n = 47), and control sub-
jects (n = 25). While no difference was detected for patients 
with New York Heart Association class I–II, HGF was signifi-
cantly increased in advanced HF patients (New York Heart 
Association class III–IV) in both CD and DCM groups, com-
pared with healthy subjects. There was a strong correlation 
between HGF and left ventricular ejection fraction in CD pa-
tients. However, there was no correlation in patients with 
 Received: November 15, 2011
 Accepted after revision: January 11, 2012
 Published online: May 3, 2012
 
 Prof. Thomas Walther
 Centre for Cardiovascular and Metabolic Research
 Hull York Medical School, University of Hull
 Hull HU6 7RX (UK)
 Tel. +44 1482 46 5513, E-Mail thomas.walther   @   hyms.ac.uk 
 © 2012 S. Karger AG, Basel
 0008–6312/12/1214–0240$38.00/0 
 Accessible online at:
 www.karger.com/crd 
For editorial comment see p. 237 
 HGF in Chagas’ Disease  Cardiology 2012;121:240–246 241
CD is fast becoming an important health issue in the USA 
and Canada, in many parts of Europe like Spain and 
France, and the Western Pacific, where an increasing 
number of infected individuals have been identified  [3] .
 CD has two successive phases: acute and chronic. The 
acute phase lasts 6–8 weeks. Once the acute phase sub-
sides, most infected patients recover an apparently healthy 
state, in which no organ damage can be detected using 
the current standard methods of clinical diagnosis. The 
infection can only be confirmed by serological or parasi-
tological tests. This form of the chronic phase of CD is 
known as the intermediate form  [4] . Most patients re-
main in this part of the chronic stage indefinitely.
 However, several years after entering the chronic phase, 
25–30% of infected individuals, depending on the geo-
graphical area, will develop irreversible lesions of the auto-
nomic nervous system in the heart, esophagus and colon, 
and of the peripheral nervous system. The chronic phase 
lasts for the duration of the infected individual’s life  [5] .
 Cardiac involvement, the most frequent and serious 
manifestation of chronic CD, typically produces atrial and 
ventricular arrhythmias, conduction defects, heart failure 
(HF), cardiomegaly, apical aneurysms, thromboembolic 
complications, or sudden death. CD remains the leading 
cause of heart disease in Latin America. Once HF devel-
ops, life expectancy is reduced to a few years. The mortal-
ity rate caused by sudden death is about 40% in CD patients 
with HF. Thus, sudden death and HF together account for 
most of the deaths that occur in patients with CD.
 HF due to CD and dilated cardiomyopathy from other 
causes (DCM) is often characterized by a progressive re-
modeling of the left ventricular (LV) chamber. Ventricu-
lar remodeling is related to various processes such as car-
diomyocyte loss due to necrosis or to apoptosis, hypertro-
phic responses of cardiomyocytes in the surviving regions 
of the left ventricle, angiogenesis, and an architectural 
rearrangement of the extracellular matrix  [6, 7] .
 Hepatocyte growth factor (HGF), originally identified 
as a potent mitogen for hepatocytes, is reported to have 
mitogenic, antiapoptotic, angiogenic, and antifibrotic ac-
tivities in various cell types  [8] . Recent experimental 
studies have implicated HGF in the process of ventricular 
remodeling and have suggested its cardioprotective ef-
fects  [9–12] . The endogenous HGF system protects the 
heart via an antiapoptotic effect on cardiomyocytes and 
attenuates the development of HF with increased angio-
genesis and decreased apoptosis and fibrosis  [7] .
 There has been no previous study regarding plasma 
HGF measurements in CD patients and in a well-defined 
group of patients with DCM. Thus, the aim of our study 
was: (1) to measure plasma HGF concentration in CD pa-
tients and compare it with those in healthy human volun-
teers, evaluating the measurement of HGF as a possible 
screening tool for ventricular dysfunction; (2) to investi-
gate a possible correlation with the functional New York 
Heart Association (NYHA) class and LV ejection fraction 
(LVEF); (3) to evaluate the prognostic impact of plasma 
HGF for cardiac death and the necessity for heart trans-
plant in CD; and (4) to compare the circulating HGF lev-
els of CD patients with those having DCM due to other 
causes, characterizing HGF as a possible diagnostic 
marker to differentiate between the two types of HF.
 Methods
 Patients
 An institutional review committee approved the study, and all 
patients gave written consent. The study population consisted of 
a prospective cohort of 138 patients from the Heart Failure Centre 
of Felicio Rocho Hospital, Brazil, enrolled between July 2001 and 
January 2005. Ninety-one consecutively recruited patients with at 
least 2 positive serologies for CD (the CD group) and 47 patients 
with negative serology for CD (the idiopathic DCM group) were 
studied and compared with 25 adjusted gender- and age-matched 
healthy subjects.
 Clinical data including medical history, physical examination, 
resting electrocardiogram (ECG), and echocardiographic param-
eters were collected by the same investigator, as reported previ-
ously  [5, 13, 14] . Systolic LV dysfunction was defined by an LVEF 
of  ! 50%, as assessed by transthoracic echocardiography (Teich-
holz method).
 Other structural cardiac diseases and comorbidities were ex-
cluded in both groups by medical history, physical examination, 
ECG, M-mode, 2-dimensional and Doppler echocardiography. Pa-
tients with valvular heart disease, coronary artery disease, con-
genital disease, acute myocarditis, hypertensive disease, renal fail-
ure (plasma creatinine  1 0.2 mmol/l), chronic pulmonary disease, 
hepatic cirrhosis, active infection, and endocrine disease have not 
been included into the study. Patients with ventricular dysfunction 
received standard pharmacologic therapy according to the NYHA 
functional class and were clinically stable for at least 30 days.
 Patients with advanced refractory HF were considered to be 
heart transplant candidates and were listed for the procedure in 
the absence of a contraindication. The control group consisted of 
healthy subjects attending the hospital clinics for a physical 
checkup. They had no cardiac symptoms or history, no comor-
bidities, and were not taking any medication.
 The study patients were prospectively defined and subdivided 
into 5 groups: group 1 (n = 46), CD without systolic ventricular 
dysfunction (LVEF  1 50%); group 2 (n = 22), CD with ventricular 
systolic dysfunction (LVEF  ! 50%) in NYHA classes I–II; group 3 
(n = 23), CD with ventricular systolic dysfunction (LVEF  ! 50%) 
in NYHA classes III–IV; group 4 (n = 21), DCM with ventricular 
systolic dysfunction (LVEF  ! 50%) in NYHA classes I–II; and 
group 5 (n = 26), DCM with ventricular systolic dysfunction 
(LVEF  ! 50%) in NYHA classes III–IV.
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 Patients were followed for incidences of cardiac death or heart 
transplant from the time the blood sample was obtained for HGF 
analysis until endpoints were reached or until the follow-up clos-
ing date in January 2006. Long-term follow-up of each patient was 
conducted by medical visit or telephone interview every 3 months. 
For those hospitalized during follow-up, the hospital records were 
reviewed. For all subjects who died, the nearest relative was con-
tacted.
 Plasma Samples and HGF Measurement
 To measure HGF in plasma, blood samples (10 ml) were taken 
from an antecubital vein and transferred into tubes containing 
ethylenediaminetetraacetic acid. Immediately after sampling, 
plasma was separated by centrifugation at 4,000  g for 10 min, fro-
zen at –80   °   C for further analysis. Before collecting blood samples, 
patients had been treated for at least 3 months, and their clinical 
symptoms were stable.
 Plasma concentrations of HGF were measured using the Bio-
Plex system that combined the principle of a sandwich immuno-
assay with the Luminex fluorescent-bead-based technology (Bio-
Rad Laboratories)  [15] .
 Statistical Analysis
 All data were expressed as the mean  8 standard error of the 
mean (SEM). We tested associations between plasma HGF con-
centrations and clinical variables using the Mann-Whitney U 
test. Because data were normally distributed, Pearson’s correla-
tion coefficient (r) was used to analyze the correlation between the 
‘investigated’ HGF in CD and DCM patient groups – they were 
tested against the null hypothesis that the correlation coefficient 
is 0. A p value  ! 0.05 was defined as significant. We used the 
Kaplan-Meier analysis to compare the survival or necessity for 
heart transplantation of patients with CD and DCM depending 
on different HGF concentrations.
 Results
 Baseline characteristics of patients and controls ac-
cording to the NYHA functional class, ECG, echocardio-
graphic parameters, and medications are summarized in 
 table 1 . The mean duration of follow-up was 36.9 months 
(range 13–54). By the end of the study, the survival status 
of all patients was known; 29 patients had died and 12 
patients received a heart transplant.
 Systolic blood pressure was significantly altered in pa-
tients in the CD group and in patients in the DCM group 
with advancing HF in comparison with the control group 
or patients with CD without systolic ventricular dysfunc-
tion.  Table 1 also illustrates increased impairment of car-
diac function in both patients with CD and in patients 
with DCM with increasing NYHA class.
 All patients with ventricular dysfunction received 
standard medical therapy according to their functional 
classes and the treatment guideline recommendations, as 
summarized in  table 1 . Almost all patients with ventricu-
lar dysfunction were given angiotensin-converting en-
zyme inhibitors (ACEIs) or angiotensin receptor block-
ers; 21 patients with DCM were taking carvedilol, but 
only 3 patients with CD were receiving   -blocker therapy. 
This lack in   -blocker treatment in patients with CD re-
sulted from missing experience with   -blockers in CD, 
because all the major trials on HF exclude patients with 
CD. Moreover, this disease is very often characterized by 
bradyarrhythmias and advanced atrioventricular block, 
which makes it difficult to use   -blockers.
 The individuals in the control group presented with 
normal and homogenous HGF levels (240.2  8 27.36 pg/
ml), as described in the literature ( fig. 1 a)  [16, 17] . Patients 
with CD without systolic ventricular dysfunction have 
been characterized by unaltered HGF levels (242.5  8 
16.88 pg/ml). While patients with DCM and CD in 
NYHA classes I and II were also characterized by unal-
tered HGF plasma levels, these plasma concentrations 
significantly increased in patients with NYHA classes III 
and IV (p  ! 0.001;  fig. 1 a).
 Because we were interested in finding out whether the 
HGF levels are related to impaired cardiac function in 
patients with CD and patients with DCM, we first per-
formed a correlation analysis to detect a possible correla-
tion between HGF and LVEF. While both parameters 
correlated with high significance in CD patients of NYHA 
I–IV (p  ! 0.01) ( fig. 1 b), there was no correlation in the 
patients with DCM (p = 0.1498) ( fig. 1 c). Moreover, the 
data summarized in  figure 1 d show that half of the mon-
itored cardiac parameters recorded by echocardiography 
( table 1 ) evidenced a correlation with the circulating HGF 
concentration in patients with CD, with the correlation 
reaching significance for the parameters: LVEF (p = 
0.0013), LV systolic dysfunction (p = 0.017), and LV end-
systolic volume (p = 0.024). However, there was no sig-
nificant correlation between HGF and any echocardio-
graphic parameters in patients with DCM.
 To find out what led to this discrepancy in correlation 
between HGF and echocardiographic parameters, we 
compared the medical treatment for patients with CD 
and DCM. Only 3 patients from the CD group received 
  -blockers, but approximately half of DCM patients took 
them. To exclude the possible role of   -blockers on HGF 
in DCM patients preventing a significant correlation as 
seen in patients with CD, we further analyzed the sub-
populations without   -blocker treatment. As for the 
whole set ( fig. 1 a), in both CD and DCM patients who 
were not on   -blocker therapy, there was still no signifi-
cant alteration in plasma HGF levels in NYHA classes I 
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and II, but the plasma concentrations increased signifi-
cantly in patients with NYHA classes III and IV as com-
pared to controls (p  ! 0.001;  fig. 2 a). Notably, the DCM 
patients with NYHA classes I and II had a trend for eleva-
tion in HGF levels. Furthermore, LVEF still evidenced a 
significant correlation with the circulating HGF concen-
tration in CD patients without   -blocker therapy (p  ! 
0.01;  fig. 2 b), while in DCM patients without   -blocker 
therapy, the correlation was even impaired (p = 0.5058) 
compared to the whole DCM group (p = 0.1498) ( fig. 2 c).
 There were deaths from pump failure (NYHA class 
I–II, n = 6; NYHA class III–IV, n = 11) and heart trans-
plants (NYHA class IV, n = 6) in the CD group, whereas 
in the DCM group, 6 patients underwent a heart trans-
plantation (NYHA class II, n = 1; NYHA class III, n = 1; 
NYHA class IV, n = 4) and 12 patients died (NYHA class 
I, n = 1; NYHA class III, n = 11). The receiver operating 
characteristic curve was generated to find a cut-off value 
for plasma HGF in CD patients ( fig.  3 a). To find out 
whether the HGF cut-off value (314.3 pg/ml) has any 
prognostic potency for the lethality of patients with CD 
and DCM, Kaplan-Meier curves were generated using 
this cut-off value to divide the patients with CD and pa-
tients with DCM into 2 subgroups. Classical statistics vi-
sualized no significant predictive value of HGF plasma 
concentration for risk in lethality or the necessity for 
heart transplantation in both CD patients (NYHA I–IV) 
and DCM patients ( fig. 3 b, c).
 Table 1.  Patient characteristics
 Groups  Control
 (n = 25) 
 CD  D CM 
 0  NYHA I–II  NYHA III–IV  NYHA I–II  NYHA III–IV 
 (n = 46)  (n = 22)  (n = 23)  (n = 21)  (n = 26) 
 Age, years 53.982.9 52.081.5 50.682.3 48.981.9 49.883.6 47.282.4 
 Sex
 Male
 Female 
 
12
13 
 
11
35 
 
9
13 
 
13
10 
 
13
8 
 
16
10 
 SBP, mm Hg  121.082.1  125.782.1  110.382.2**, ### 98.782.9***, ###  112.882.8# 95.984.6***, ### 
 DBP, mm Hg 76.480.98 78.981.2 73.381.3 70.381.8### 73.981.5 70.881.8### 
 HR, bpm 73.681.2 69.581.3 69.882.1 75.082.5 72.982.0 83.282.2**, ### 
 ECG 
 Normal/abnormal 25/0 13/33 0/22 0/23 0/21 0/26 
 Pacemaker 0 4 6 3 1 1 
 ECHO 
 LVEF, % 67.581.1 37.882.0### 24.581.5### 37.282.2### 23.481.3### 
 LVDD, mm 51.981.0 62.781.6### 70.981.3### 64.782.1### 74.982.0### 
 LVSD, mm 32.680.90 50.681.8### 62.181.3### 52.882.1### 66.682.1### 
 LVEDV, ml  131.586.8  204.1812.0#  303.4820.2###  217.7816.8#  358.4836.3### 
 LVESV, ml 41.883.0  109.8810.7##  209.5810.7###  137.5813.5###  256.9828.8### 
 Pharmacotherapy 
 No medication 25 31 0 – – – 
 ACEI – 3 21 21 19 15 
 -Blocker – 1 2 – 13 8 
 ARB – – 1 1 2 8 
 Amiodarone – 4 4 6 3 2 
 Diuretic – 3 17 21 19 25 
 Digoxin – 2 10 19 12 22 
 Spironolactone – – 4 14 13 19 
 Anticoagulant – 3 2 6 2 8 
 Dat a are given as the average 8 SEM. ** p < 0.01, *** p < 0.001 vs. control; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the CD 0. Abnor-
mal ECG includes arrhythmias, flutter and atrial fibrillation, any bundle branch block, atrioventricular block and atrial/ventricular 
hypertrophy. SBP = Systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; ECHO = echocardiography; LVDD = LV 
diastolic diameter; LVSD = LV systolic diameter; LVEDV = LV end-diastolic volume; LVESV = LV end-systolic volume; ARB = angio-
tensin AT1 receptor blocker. 
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 Discussion
 Despite recent advances in diagnosis and management 
of HF, it is still an important public health problem world-
wide. Therefore, it is very important to identify HF patients 
with a high risk to develop cardiovascular events in time 
and to prevent their onsets by prompt and proper treat-
ments. Plenty of clinical and molecular markers have been 
identified to have prognostic potency, and a combination 
of several markers has been confirmed to have additive 
beneficial effects for risk prediction  [18] . However, it is still 
desirable to discover novel biomarkers for risk stratifica-
tion in particular HF populations with different etiology.
 HGF is such a new molecular marker to predict mortal-
ity in congestive HF patients  [7, 19, 20] . It was even dis-
cussed that HGF may become the next B-type natriuretic 
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 tion between HGF and other echocardiographic parameters was 
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peptide which is the most commonly used biomarker for 
cardiovascular diseases  [21] . In the present study, we fo-
cused on two specific HF patient populations with HF 
caused by either CD or idiopathic DCM, which were not 
included in previous clinical trials. Plasma HGF was iden-
tified to be significantly increased in patients with ad-
vanced HF (NYHA class III–IV) but not in patients with 
mild to moderate severity (NYHA class I–II). However, in 
our present study, HGF concentration in HF patient plas-
ma was lower than the values reported by Lamblin et al. 
 [7] and Rychli et al.  [19] . One explanation could be the dif-
ferent methods used. In our study, we used the Bio-Plex 
Pro TM  Assays system (Bio-Rad), while in the other two 
studies, the traditional ELISA kit for HGF was used. How-
ever, the most possible reason is the different composition 
of recruited patients and treatments they received. It was 
confirmed by different clinical trials that circulating HGF 
concentration was positively correlated with age and clin-
ical severity  [7, 19] . In the report by Rychli et al.  [19] , the 
median age of recruited patients is even 75 years and only 
advanced HF patients were included. However, the aver-
age age of HF patients in our present study is only 49 years 
and patients from NYHA class I–IV were included.
 It was reported that HGF concentration was markedly 
increased in patients with congestive HF at admission and 
gradually returned to normal level during hospitalization 
 [20] . Therefore, it is reasonable to assume that different 
treatment may also influence HGF concentration. Since 
in the study described by Rychli et al.  [19] only hospital-
ized HF patients with clinical signs and symptoms of car-
diac decompensation (NYHA class III-IV) were included, 
and blood was collected in the morning of the day of dis-
charge before intake of medication, this might explain the 
higher concentration and positive predictive value. In an-
other study, peripheral blood was collected for HGF mea-
surement at the time of entry into the study  [7] . In our 
present study, the heart function of all patients was com-
pensated and they were treated with maximal tolerated 
doses of ACEIs, angiotensin receptor blockers, and others, 
for at least 3 months before the blood was obtained. Since 
the dose of ACEIs had been discovered to be inversely cor-
related with HGF concentration  [19] , and in the present 
study, most of the patients received ACEI therapy, this 
may also be part of the reasons why the HGF concentra-
tion measured was lower than previously described.
 Although CD lead to typical DCM, it is not clear why 
there is a close correlation between HGF and echocardio-
graphic parameters in CD patients but not in idiopathic 
DCM patients. We found that   -blocker treatment was 
not responsible for this discrepancy. It would be very in-
teresting if a different DCM etiology may have an impact 
on the generation or the metabolism of HGF, and thus for 
the concentration of circulating HGF. If this can be prov-
en, it might change our general understanding of dilated 
cardiomyopathy, since it is generally believed that the 
phenotype of dilated cardiomyopathy itself but not the 
causes for the phenotype determine the regulation of bio-
markers of interest. However, further investigation with 
more patients per specific etiology is required to clarify 
such mechanisms.
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 Although HGF had been identified to be a predictor of 
mortality in HF patients  [7, 19] , it cannot be used to pre-
dict primary endpoints in CD and DCM patients in our 
present study. However, our data are not per se in contra-
diction to other reports. In one study, subgroup analysis 
revealed that HGF was a strong predictor only in isch-
emic HF patients but not in non-ischemic patients  [19] . In 
another study, over the time of follow-up, the percentage 
of ischemic etiology was significantly higher in patients 
with events compared to event-free patients  [7] . However, 
in our present study, patients with coronary artery dis-
eases were excluded. It seems that HGF concentration is 
mainly regulated in cardiac ischemic condition. This idea 
is further supported by the finding of Zhu et al.  [22] that 
HGF was released after acute myocardial infarction.
 In summary, although HGF concentration was signif-
icantly increased in advanced HF patients with CD and 
idiopathic DCM, our preliminary results indicate that it 
cannot be used to predict mortality or heart transplant in 
these patients. In combination with other reports, the 
conclusion can be made that etiology has to be taken into 
consideration when discussing the promising prognostic 
potency of HGF values in HF patients.
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